Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145485 | 1.00 | KDM4E (1.00) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL10434364 | 0.88 | KDM4E (0.77) | KDM4EGLAMAPTPOLBKMT2A | |
| Tetrahydrofuran SCHEMBL29092861 | 0.86 | KDM4E (0.74) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL6614986 | 0.86 | KDM4E (0.74) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL28171560 | 0.85 | KDM4E (0.73) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL5707564 | 0.83 | KDM4E (0.71) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL148392 | 0.83 | KDM4E (0.70) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL147774 | 0.83 | KDM4E (0.70) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL3898354 | 0.81 | KDM4E (0.66) | KDM4EGLAMAPTPOLBKMT2A | |
| SCHEMBL9117837 | 0.81 | KDM4E (0.66) | KDM4EGLAMAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473291-B2 | Benzodiazepine compound, preparation method therefor, and use thereof in medicine | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2025-11-18 | — | — | US | disclosed |
| CN-119161264-A | Insecticidal composition containing quinolone compounds and application thereof | 海南大学 | 2024-12-20 | — | — | CN | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220324867-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2022-10-13 | — | — | US | disclosed |
| EP-4013440-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324867-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | GABRA1, GABRA4, GABRR1 | KDM4E 833/4885GLA 4718/4885MAPT 3207/4885 |
| US-12473291-B2 | Benzodiazepine compound, preparation method therefor, and use thereof in medicine | GABRA1, GABRA4, GABRR1 | KDM4E 833/4885GLA 4718/4885MAPT 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.